About Sun Pharma ANZ
Sun Pharma is a global leader in pharmaceutical supply and manufacturing, operating in over 100 global markets, with manufacturing sites in over 40 locations around the world. Sun Pharma ANZ has been present in Australia since 2005 through our specialty pharmacy and hospital focused product portfolios and more recently has begun building an Innovator Medical Portfolio with a strong focus in dermatology, fertility treatment, optometry, and oncology.
Sun Pharma is excited to inform you that Cequa™ (ciclosporin 900 microgram/mL) is available privately for moderate to severe dry eye where artificial tears have not been sufficient (1) and on the Pharmaceutical Benefits Scheme (PBS) for chronic severe dry eye disease with keratitis (6).
Take control of dry eyes with Cequa (1,2)
Cequa is indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye) where prior use of artificial tears has not been sufficient(1). Cequa was approved by the Therapeutic Goods Administration (TGA) in January 2020 and has been available via private prescription since November 2022 and is now available on the PBS for a subsection of patients that meet authority criteria. Ciclosporin is a Stage 2 guideline (TFOS DEWS II)(3) recommended therapy that optometrists can prescribe.
When artificial tears have not been sufficient (1)
Patients who experience insufficient relief from dry eye using artificial tears can now be started on Cequa. Cequa can be ordered by pharmacies from all major pharmaceutical wholesalers. Patients can access treatment with a private prescription or with a PBS prescription under authority criteria.
Cequa is an aqueous nanomicelle solution improving signs of dry eye from 28 days (2,4-5)
Cequa has been engineered using our unique nanomicelle technology to deliver ciclosporin where it's needed most(2,3-5)and has been found to significantly reduce corneal staining at 28 days vs vehicle (p<0.01)(2).
Sun Pharma believes that Cequa is a valuable new addition to your dry eye treatment options. Patient Starter Packs are readily available and are a useful way to start patients on Cequa. All Cequa patients can be started on 1 Patient Starter Pack of 10 ampoules with their initial Cequa prescription. Patient Starter Packs help identify >4% of patients that discontinue use due to instillation site pain(2). To request your free Patient Starter Packs, please email cequa.samples@sunpharma.com
The Sun Pharma team will be available at this booth during morning tea, lunch and afternoon breaks. If you have additional questions regarding Cequa or would like to speak to a company representative, please email our customer service team at customerservice.aus@sunpharma.com
Sun Pharma believes that Cequa is a valuable new addition to your dry eye treatment options. Patient Starter Packs are readily available and are a useful way to start patients on Cequa. All Cequa patients can be started on 1 Patient Starter Pack of 10 ampoules with their initial Cequa prescription. Patient Starter Packs help identify >4% of patients that discontinue use due to instillation site pain(2). To request your free Patient Starter Packs, please email cequa.samples@sunpharma.com
The Sun Pharma team will be available at this booth during morning tea, lunch and afternoon breaks. If you have additional questions regarding Cequa or would like to speak to a company representative, please email our customer service team at customerservice.aus@sunpharma.com
PBS Information: Authority Required. Refer to PBS Schedule for full information.
Please review product information available at this virtual trade display.
Reference: 1. Cequa Approved Product Information. 2. Goldberg DF et al. Ophthalmology 2019; 126:1230–7. 3. Tauber J et al. Clin Ophthalmol 2018; 12:1921–9. 4. Vaishya R et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014; 6:422–37. 5. Weiss SL et al. J Ocul Pharmacol Ther 2019; 35:395–402. 6
Sun Pharma ANZ Pty Ltd ABN 17 110 871 826, Macquarie Park NSW 2113 Ph: 1800 726 229. Fax: +61 2 8008 1613.
Med Info: 1800 726 229 Adverse events may be reported to Sun Pharma by either email: adverse.events.aus@sunpharma.com or phone: 1800 726 229. Date of preparation: March 2023. CEQ2023/03OVC